184177-83-1

• 常用中文名：泊沙康唑侧链
• 常用英文名：2-[(1S,2S)-1-Ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one
• CAS号：184177-83-1
• 分子式：C₃₀H₃₅N₅O₃
• 分子量：513.631
• 发布时间：2018-07-31 22:15:00
• 更新时间：2026-07-02 22:42:57

名称

• 中文名: 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮
• 英文名: 2-[(1S,2S)-1-ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-Triazol-3-one
• 中文别名: 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮 /1-((2S,3S)-2-(BENZYLOXY)PENTAN-3-YL)-4-(4-(4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL)PHENYL)-1H-1,2,4-TRIAZOL-5(4H)-ONE; 泊沙康唑中间体O; 4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1; 羟基三唑杂质; 泊沙康唑中间体POS-B; 1-((2S,3S)-2-(苄氧基)戊-3-基)-4-(4-(4-(4-羟基苯基)哌嗪-1-基)苯基)-1H-1,2,4-三氮唑-5(4H)-酮; 泊沙康唑/泊沙康唑侧链; 2-((2S,3S)-2-(苯甲氧)戊-3-基)-4-(4-(4-(4-羟苯基)哌嗪-1-基)苯基L)-2,4-二氢-3H-1,2,4-三氮唑-3-酮; 4-三氮唑-3-酮; 泊沙康唑杂质92; 泊沙侧链3; 2-((1S,2S)-1-乙基-2-苄氧基丙基)-2,4-二氢-4-(4-(4-(4-羟基…; 2-(2(S)-苄氧基-1(S)-乙基-丙基)-4-{4-[4-(4-羟基-苯基)- 哌嗪-1-基]-苯 基}-2,4-二氢-[1,2,4]三唑-3-酮; 泊沙康唑中间体10; 4-(4-(4-(4-羟苯基)-1-哌啶基)苯基)-2-[(1S,2S)-1-乙基-2-(苄氧基)丙; 泊沙侧链; 6-氯喹啉-38-甲酸; 泊沙康唑-2; 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H; 泊沙康唑POSA中间体; 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-呱嗪基]苯基]-3H-1,2,4-三氮唑-3-酮-(泊沙康唑中间体); 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌氰基]苯基]-3H-1,2,4-三氮唑-3-酮; 泊沙康唑中间体0; 泊沙康唑中间体POB; 泊沙康唑非对映异构体相关化合物6; 2S)-1-乙基-2-苄氧基丙基]-2; 4-(4-(4-(4-羟苯基)-1-哌啶基)苯基)-2-[(1S,2S)-1-乙基-2-(苄氧基)丙基]-2,4-二氢-3H-1,2,4-三唑-3-酮(泊沙康唑杂质); 泊沙康唑INT2; POB泊沙康唑中间体(POB); 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4 -[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮 (泊沙康唑侧链); 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮泊沙康唑中间体; 2-((1S,2S)-1-乙基-2-苄氧基丙基)-2,4-二氢-4-(4-(4-(4-羟基苯基)-1-哌嗪基)苯基)-3H-1,2,4-三氮唑-3-酮; POB 泊沙康唑中间体（POB); 4-(4-(4-(4-羟苯基)-1-哌啶基)苯基)-2-[(1S,2S)-1-乙基-2-(苄氧基)丙基]-2,4-二氢-3H-1,2,4-三唑-3-酮; 泊沙康唑中间体B; 泊沙康唑侧链C3; 泊沙康唑中间体3; 泊沙康唑非对映异构体相关化合物7; 2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-(4-羟苯基)-1-哌嗪]-3H-1,2,4-三唑-3-酮; (1S,2S)-1-ETHYL-2-BEZYLOXYPROPYL]-2,4-DIHYDRO-4-[4-[ 4-(4-HYDROXYPHENYL)-1-PIPERAZINYL]PHENYL]- 3H-1,2,4- TRIAZOL-3-ONE2-[(1S,2S)-1-基-2-苄氧基丙基]-2,4-氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮; 泊沙康唑中间体(2-[(1S,2S)-1-乙基-2-苄氧基丙基]-2,4-二氢-4-[4-[4-(4-羟基苯基)-1-哌嗪基]苯基]-3H-1,2,4-三氮唑-3-酮)
• 英文别名: 2-[(1S,2S)-2-benzyloxy-1-ethyl-propyl]-4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-1,2,4-triazol; 2-benzyl-1-(((2R,4R)-2-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((2S,3S)-2-hydroxypentan-3-yl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)piperazin-1-yl)phenoxy)methyl)tetrahydrofuran-2-yl)methyl)-1H-1,2,4-triazol-2-ium chloride; Posaconazole Process Related Impurity; (S),(S)2-(2-benzyloxy-1-ethyl propyl)-4-{4-[4–(4 hydroxy-phenyl)-piperzine-1-yl]-phenyl}-2,4-dihydro-[1,2,4]triazole 3 one; Anticancer agent; Posaconazole synthetic intermediate; PSZ-2; 2-[(2S,3S)-2-(Benzyloxy)-3-pentanyl]-4-{4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; Posaconazole Diastereoisomer Related Compound 6; 2-[(1S,2S)-1-Ethyl-2-(phenylmethoxy)propyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one; 2-((2S,3R)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2H-1,2,4-triazol-3(4H)-one; 2-[(1S,2S)-1-Ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperozinyl]phenyl]-3H-1,2,4-triazol-3-one; Posaconazole Impurity 87; Posaconazole Diastereoisomer Related Compound 7; 2-(2(S)-Benzyloxy-1(S)-ethyl-propyl)-4-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-2,4-dihydro-[1,2,4]triazol-3-one; 2S)-1-ethyl-2-bezyloxypropyl]-2; Posaconazole Impurity 92; 3H-1,2,4-Triazol-3-one, 2-[(1S,2S)-1-ethyl-2-(phenylMethoxy)propyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]; 1-((2S,3S)-2-(Benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one; 2-[(1S,2S)-2-benzyloxy-1-ethyl-propyl]-4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; Posaconazole int2; 2-((1S,2S)-1-ethyl-2-benzyloxyl-propyl-1-yl)-2,4-diH-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-3H-1,2,4-triazol-3-one; 1-((2S,3S)-2-(Benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)-piperazin-1-yl)phenyl)-1H-1,2,4; Posa-O 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one; 2-[(1S,2S)-1-Ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one - (posaconazole intermediate); Posaconazole Intermediate2; [S-(R*,R*)]-2-[1-Ethyl-2-(phenylMethoxy)propyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one; 2-(2(S)-Bezyloxy-1(S)-ethyl-propyl)-4-{4-[4-(4-hydroxyphenyl)-piperazin-1-yl]-phenyl}-2,4-dihydro-[1,2,4]triazol-3-one; ChemicalBook; 2-[(1S,2S)-1-Ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]; 2-[(1S,2S)-1-Ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4; 2-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-[(1S,2S)-1-Ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]- 3H-1,2,4-triazol-3-one; Side chain of Posaconazole side chain of Posaconazole; Posaconazole Intermediate 3; Posaconazole Intermediate 1; Posazonazole intermediate POB; Posaconazole POB; 2-[(1S,2S)-1-ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]- 3H-1,2,4-Triazol-3-oneChemicalBook; Posaconazole inter-2 3H-1,2,4-Triazol-3-one,2-[(1S,2S)-1-ethyl-2-(phenylMethoxy)propyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]; 4-Triazol-3-one; 4-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-2-[(2S,3S)-2-phenylmethoxypentan-3-yl]-1,2,4-triazol-3-one; US-DMF No.; 2-[(1S,2S)-1-ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]- 3H-1,2,4-Triazol-3-one; 2-((2S,3R)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-2H-1,2,4-triazol-3(4H)-one (Posaconazole intermediate); Posacozole Diastereoisomer Related Compound 6; 1-((2S,3S)-2-(Benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (Posaconazole Impurity); Posaconazole side chain; 1-[(2S,3S)-2-(benzyloxy)pentan-3-yl]-4-{4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 1-((2S,3S)-2-(Benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)-piperazin-1-yl)phenyl)-1H-1,2,4-tr; POSACONAZOLE CAS 171-2 INTERMEDIATES; BSKZ-2; Best price and High purity supply of Posaconazole Intermediate; 4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]- 3H-1; :2-[(1S,2S)-1-ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-Triazol-3-one; Posaconazole Intermediate-B; 2-[(1S,2S)-1-Ethyl-2-benzyloxypropyl]-2,4-dihydro-4-[4-[4-(4; Posaconazole B; Posaconazole Hydroxy O-Benzyl Impurity

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 685.4±65.0 °C at 760 mmHg
• 分子式: C₃₀H₃₅N₅O₃
• 分子量: 513.631
• 闪点: 368.3±34.3 °C
• 精确质量: 513.273987
• PSA: 75.76000
• LogP: 3.60
• 外观性状: 灰色固体
• 蒸汽压: 0.0±2.2 mmHg at 25°C
• 折射率: 1.632
• 储存条件: 2-8℃，密闭，干燥

上下游产品

上游产品  0
下游产品  1
170985-86-1